The role of Adamts in Cerebral Cavernous Malformation (CCM) disease

In the project above, I planned to test whether genetically and pharmacologically inhibiting Adamts in CCM disease can be utilised as a therapeutic target for Cerebral Cavernous Malformations (CCMs). Since I received the grant, I have identified an FDA approved drug, Ponatinib, which can effectively target MEKK3-KLF-ADAMTS pathway to prevent CCM formation and growth in…

Collaboration between Duke University, University of Chicago, and the Barrow Neurological Institute

Repurposing Propranolol as Potential Therapy for CCM The goal of [Dr. Doug Marchuk’s] research lab [at Duke University School of Medicine] is to understand the underlying mechanisms of CCM formation, to use this knowledge to generate a mouse model of the disease that faithfully copies the features seen in the human disease, and finally, to…

Be Brave for Life Awards $150,000 in Micro-Grants, April 2018

Be Brave for Life is excited to announce that we just awarded $150,000 in Micro-Grants to 8 deserving benign brain tumor and cerebrovascular disease research initiatives